WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that several abstracts regarding regimens containing either ABT-493 or paritaprevir, Enanta’s protease inhibitors being developed through its collaboration with AbbVie, as well as an abstract regarding EDP-494, Enanta’s wholly-owned pan-genotypic cyclophilin inhibitor for HCV infection, have been accepted for presentation at The International Liver Congress™ (ILC) 2016, in Barcelona, Spain, April 13-17.
